Dihydropyrimidine Dehydrogenase (NADP+)

Dihydropyrimidine Dehydrogenase (NADP+) (DPD) is an enzyme that plays a crucial role in the metabolism of pyrimidines, which are essential components of nucleic acids. DPD catalyzes the initial and rate-limiting step in the catabolism of uracil and thymine, which are pyrimidine bases, converting them into dihydrouracil and dihydrothymine, respectively. This process is vital for the maintenance of the nucleotide pool balance within the cell and for the elimination of excess or damaged pyrimidine bases. The enzyme is encoded by the DPYD gene in humans.

Function

DPD functions by reducing pyrimidine bases, uracil, and thymine, using NADPH as a cofactor. This reduction is essential for the degradation of these bases, allowing for their removal from the body or their recycling for the synthesis of new nucleic acids. The activity of DPD is critical in both normal cellular function and the metabolism of certain drugs, such as the chemotherapeutic agent 5-fluorouracil (5-FU). Inhibition or deficiency of DPD can lead to toxic accumulation of pyrimidines and 5-FU, resulting in severe side effects during chemotherapy.

Genetics

The DPYD gene, located on chromosome 1p22, encodes the DPD enzyme. Variants in the DPYD gene can significantly affect the enzyme's activity, leading to DPD deficiency. This condition is characterized by a reduced ability to metabolize uracil and thymine, leading to their accumulation in the body. Individuals with DPD deficiency may experience a range of symptoms, from mild to severe, including neurological and developmental issues. Moreover, these individuals are at a higher risk of experiencing severe toxicity when treated with 5-FU or related drugs.

Clinical Significance

DPD plays a significant role in the pharmacokinetics of certain drugs, most notably 5-FU, which is used in the treatment of various cancers. The enzyme's activity directly influences the efficacy and toxicity of 5-FU. Patients with reduced or deficient DPD activity are at a higher risk of developing severe, potentially life-threatening toxicities when treated with 5-FU. Therefore, screening for DPD deficiency is recommended before initiating 5-FU chemotherapy to adjust the dose accordingly and prevent adverse effects.

DPD Inhibitors

Several inhibitors of DPD have been developed to enhance the efficacy of 5-FU by preventing its breakdown and allowing for higher drug concentrations at the tumor site. These inhibitors, such as eniluracil, are used in combination with 5-FU in certain treatment protocols to improve therapeutic outcomes. However, the use of DPD inhibitors requires careful monitoring due to the increased risk of toxicity, especially in patients with underlying DPD deficiency.

Conclusion

Dihydropyrimidine Dehydrogenase (NADP+) is a vital enzyme in the metabolism of pyrimidines and certain chemotherapeutic agents. Its activity has significant implications for both normal cellular function and the treatment of cancer. Understanding the genetics and function of DPD is crucial for optimizing chemotherapy regimens and minimizing the risk of drug toxicity.

• Need help finding a doctor or specialist anywhere in the world? WikiMD's DocFinder can help with millions of doctors!

This article is a stub. Help WikiMD grow by registering to expand it. Editing is available only to registered and verified users. About WikiMD: A comprehensive, free health & wellness encyclopedia.